Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Filings indexed 1,129 across all filing types
Latest filing 2020-11-18 Director's Dealing
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-11-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-03 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-02 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or agreements by a company. The text describes a material definitive agreement between Apellis Pharmaceuticals and Swedish Orphan Biovitrum AB, detailing the collaboration and license agreement terms. It includes no financial statements or detailed financial performance data, but rather an announcement of a significant business transaction. The document also references a press release attached as an exhibit. Given these characteristics, this filing is best classified as a Capital/Financing Update (CAP), as it relates to a material agreement impacting the company's capital or business operations but is not a full financial report or earnings release.
2020-10-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.